Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epithelial aPKC deficiency leads to stem cell loss preceding metaplasia in colorectal cancer initiation.
Kinoshita H, Martinez-Ordoñez A, Cid-Diaz T, Han Q, Duran A, Muta Y, Zhang X, Linares JF, Nakanishi Y, Kasashima H, Yashiro M, Maeda K, Albaladejo-Gonzalez A, Torres-Moreno D, García-Solano J, Conesa-Zamora P, Inghirami G, Diaz-Meco MT, Moscat J. Kinoshita H, et al. Among authors: muta y. Dev Cell. 2024 Aug 5;59(15):1972-1987.e8. doi: 10.1016/j.devcel.2024.05.001. Epub 2024 May 29. Dev Cell. 2024. PMID: 38815584
Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer.
Martinez-Ordoñez A, Duran A, Ruiz-Martinez M, Cid-Diaz T, Zhang X, Han Q, Kinoshita H, Muta Y, Linares JF, Kasashima H, Nakanishi Y, Omar M, Nishimura S, Avila L, Yashiro M, Maeda K, Pannellini T, Pigazzi A, Inghirami G, Marchionni L, Sigal D, Diaz-Meco MT, Moscat J. Martinez-Ordoñez A, et al. Among authors: muta y. Cancer Cell. 2023 Feb 13;41(2):252-271.e9. doi: 10.1016/j.ccell.2022.11.016. Epub 2022 Dec 15. Cancer Cell. 2023. PMID: 36525970 Free PMC article.
Pancreatic RECK inactivation promotes cancer formation, epithelial-mesenchymal transition, and metastasis.
Masuda T, Fukuda A, Yamakawa G, Omatsu M, Namikawa M, Sono M, Fukunaga Y, Nagao M, Araki O, Yoshikawa T, Ogawa S, Masuo K, Goto N, Hiramatsu Y, Muta Y, Tsuda M, Maruno T, Nakanishi Y, Masui T, Hatano E, Matsuzaki T, Noda M, Seno H. Masuda T, et al. Among authors: muta y. J Clin Invest. 2023 Sep 15;133(18):e161847. doi: 10.1172/JCI161847. J Clin Invest. 2023. PMID: 37712427 Free PMC article.
Cholangiocyte organoids for disease, cancer, and regenerative medicine.
Nagao M, Fukuda A, Kashima H, Matsuyama S, Iimori K, Nakayama S, Mizukoshi K, Kawai M, Yamakawa G, Omatsu M, Namikawa M, Masuda T, Hiramatsu Y, Muta Y, Maruno T, Nakanishi Y, Tsuruyama T, Seno H. Nagao M, et al. Among authors: muta y. Eur J Cell Biol. 2024 Dec 19;104(1):151472. doi: 10.1016/j.ejcb.2024.151472. Online ahead of print. Eur J Cell Biol. 2024. PMID: 39721346 Free article.
Simultaneous activation of Kras-Akt and Notch pathways induces extrahepatic biliary cancer via the mTORC1 pathway.
Namikawa M, Fukuda A, Mizukoshi K, Iwane K, Kawai M, Yamakawa G, Omatsu M, Sono M, Masuda T, Araki O, Nagao M, Yoshikawa T, Ogawa S, Hiramatsu Y, Muta Y, Tsuda M, Maruno T, Nakanishi Y, Tsuruyama T, Taura K, Hatano E, Seno H. Namikawa M, et al. Among authors: muta y. J Pathol. 2023 Aug;260(4):478-492. doi: 10.1002/path.6139. Epub 2023 Jun 13. J Pathol. 2023. PMID: 37310065
Retinoblastoma-binding Protein 9 Suppresses Intestinal Inflammation and Inflammation-induced Tumorigenesis in Mice.
Hamada K, Nakanishi Y, Muta Y, Omatsu M, Iwane K, Ikeda M, Chen J, Masui Y, Aoyama N, Agatsuma N, Yamakawa G, Utsumi T, Kitamoto H, Okabe M, Itatani Y, Adachi T, Yasuda K, Yamamoto S, Fukuda A, Kuroda E, Ohmuraya M, Obama K, Hirota S, Ikeuchi H, Nakanishi K, Seno H. Hamada K, et al. Among authors: muta y. Cell Mol Gastroenterol Hepatol. 2024 Dec 2:101435. doi: 10.1016/j.jcmgh.2024.101435. Online ahead of print. Cell Mol Gastroenterol Hepatol. 2024. PMID: 39631567 Free article.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: muta y. Diabetes Obes Metab. 2024 Aug;26(8):3248-3260. doi: 10.1111/dom.15652. Epub 2024 May 19. Diabetes Obes Metab. 2024. PMID: 38764356
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
92 results